MedTrace Logo

Carbon Monoxide-based Rebreathing Method and Bioimpedance in Hemodialysis Patients

NCT04645121 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-06-06

No results posted yet for this study

Summary

The study is a case-control study with the primary aim of objectifying the volume status of patients receiving hemodialysis. Volume status will be assessed at dry weight and evaluated by a carbon monoxide rebreathing method, that measures blood volume, and bioimpedance that measures total body water. Case-control subjects will be matched on gender, age and weight.

Secondary aims are to evaluate the carbon monoxide rebreathing method. Blood volumes obtained by the carbon monoxide rebreathing method will be correlated to blood volumes obtained by radioactive labelling of erythrocytes and albumin. In addition, it will be investigated whether hemoglobin is a valid marker of anemia in patients receiving hemodialysis by measuring the erythrocyte volume and the hemoglobin mass by the carbon monoxide rebreathing method and correlating this to the hemoglobin concentration measured before and after dialysis.

Conditions

  • Hemodialysis Complication
  • Volume Overload

Interventions

DEVICE

Carbon Monoxide-based Rebreathing

6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.

DEVICE

Bioimpedance

Measures total volume, intra and extracellular volume.

RADIATION

Radioactive labelling of erythrocytes and albumin

Measure blood volume, plasma volume and erythrocyte volume.

Sponsors & Collaborators

  • Herlev Hospital

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-25
Primary Completion
2022-05-20
Completion
2022-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04645121 on ClinicalTrials.gov